STOCK TITAN

Clearmind Medicine Inc. Common Shares - CMND STOCK NEWS

Welcome to our dedicated page for Clearmind Medicine Common Shares news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medicine Common Shares stock.

Clearmind Medicine Inc. (NASDAQ: CMND, FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company dedicated to the discovery and development of innovative psychedelic-derived therapeutics. The company focuses on addressing widespread and under-treated health issues, particularly alcohol use disorder (AUD).

Currently, Clearmind's flagship compound, CMND-100, is in the spotlight. This MEAI-based (5-methoxy-2-aminoindane) formula has shown promising pre-clinical results in disrupting binge drinking behaviors without inducing hallucinations. The Israeli Ministry of Health has recently approved a Phase I/IIa clinical trial for CMND-100, marking a significant milestone in its development.

Clearmind's intellectual property portfolio is robust and growing, comprising eighteen patent families and 27 granted patents. Recent developments include nine new patent applications filed with the USPTO, highlighting compositions for treating alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders. These efforts reflect the company's commitment to expanding and protecting its IP assets.

Collaborations play a crucial role in Clearmind's strategy. The company has entered exclusive licensing agreements with institutions such as the Hebrew University of Jerusalem, further enriching its portfolio with generation 3.0 psychedelic compounds aimed at treating addiction and mental health disorders. Additionally, Clearmind has initiated a groundbreaking partnership with Yissum Research Development Company for PTSD treatments.

Another key project is Clearmind's proprietary MEAI-based alcohol substitute beverage program. This ethanol-free alternative aligns with the growing global trend towards no- and low-alcohol consumption, offering a health-focused option for consumers.

Clearmind Medicine Inc. continues to execute its intellectual property and development strategies, positioning itself at the forefront of psychedelic-based medical treatments. The company’s shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under 'CWY0'.

For more information, please visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq, CSE: CMND) recently announced the successful completion of two innovative drug-discovery projects at the Hebrew University. These projects focus on developing novel psychedelic compounds aimed at enhancing therapeutic effects for under-treated health issues. Led by esteemed professors, the initiatives involved synthesizing synthetic molecules and evaluating psychedelic analogues for efficacy and safety. The promising results from these projects will allow Clearmind and Yissum to advance multiple new patent applications, expanding the company’s intellectual property portfolio. The firm remains committed to its mission of providing innovative solutions for mental health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announced promising pre-clinical results for its drug candidate MEAI, showing potential in treating substance addiction without affecting natural reward processes. Conducted at Bar Ilan University, the in-vivo studies revealed that MEAI, at a dose of 5mg/kg, significantly decreased cocaine craving, marking it as a potential first-of-its-kind treatment for cocaine addiction. The researchers confirmed that MEAI allows for the maintenance of natural rewards, distinguishing it from traditional addiction treatments. CEO Dr. Adi Zuloff-Shani emphasized the importance of these results in addressing cocaine addiction, which currently lacks dedicated therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.13%
Tags
-
Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) has successfully manufactured batches of its MEAI-based molecule, CMND-100, for its first in-human clinical trial targeting Alcohol Use Disorder (AUD). This milestone indicates readiness to proceed with clinical testing. The drug was produced under Good Manufacturing Practices to meet FDA standards, aligning with the company's goal to develop psychedelic-derived therapeutics. Clearmind holds seven patent families and aims to expand its intellectual property portfolio as it advances its clinical program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.23%
Tags
Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announced promising pre-clinical trial results for its drug candidate MEAI, aimed at treating obesity and metabolic syndrome. Conducted at the Hebrew University of Jerusalem, the trials demonstrated a 20% weight loss in rodents, improved insulin sensitivity, and reduced liver fat. MEAI treatment also decreased sucrose preference, indicating potential applications in addiction treatment. The global obesity drug market was valued at $1.9 billion in 2021, with further growth projected. Clearmind's progress underscores the drug's potential to address significant health issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.36%
Tags
-
Rhea-AI Summary

Clearmind Medicine Inc. (NASDAQ:CMND) announces a new interview featuring CEO Dr. Adi Zuloff-Shani, discussing the company's innovative approach using non-hallucinogenic psychedelic compounds to address addiction and mental health issues. Clearmind's lead candidate, CMND-100, derived from MEAI, aims to treat alcohol use disorder and is set for clinical trials in early 2023. The company holds seven patent families and has received a patent for using MEAI as an alcohol substitute. The interview addresses the significant market need for effective treatments and outlines plans for an IND application to the FDA for clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
none
-
Rhea-AI Summary

Clearmind Medicine Inc. (CMND) held its shareholder meeting on December 28, 2022, where all proposed matters were approved. This includes the company's rolling stock option plan and an increase in options and restricted share units available for issuance. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues, holding seven patent families and planning further acquisitions of intellectual property. The company aims to commercialize its products as regulated medicines, foods, or supplements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
Rhea-AI Summary

Clearmind Medicine Inc. (CMND) announced its first first-in-human clinical trial in Israel for the MEAI-based CMND-100 compound targeting alcohol use disorder (AUD). The agreement with the IMCA center in Ramat Gan will be led by Prof. Mark Weiser. CMND plans to establish a similar agreement in the U.S.. AUD affects nearly 28 million adults in the U.S., with significant public health implications. The global AUD treatment market is projected to grow from $564 million in 2021, at an annual rate of 8.8% by 2032.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.38%
Tags
-
Rhea-AI Summary

Clearmind Medicine has received a new patent from the U.S. Patent and Trademark Office for its proprietary MEAI as a substitute for alcoholic beverages. This patent complements similar patents granted in Europe and India, marking a significant milestone in a rapidly growing market for non-alcoholic options, valued at $395 million in the U.S. with a year-on-year growth of +20.6%. The company believes that this innovative compound can generate substantial revenue outside the pharmaceutical sector. The appointment of Nicholas Kadysh bolsters regulatory navigation for this product.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
Rhea-AI Summary

Clearmind Medicine Inc. (Nasdaq: CMND) updates shareholders on its progress towards FDA approval for its proprietary compound CMND-100, a treatment for Alcohol Use Disorder (AUD). The company has completed required non-clinical studies and is nearing its first human clinical trial. Clearmind is also exploring MEAI's potential for cocaine addiction and other mental health issues. The firm completed a $7.5 million U.S. IPO and uplisted to Nasdaq, enhancing its market presence. Future plans include advancing its IP portfolio and targeting new drug candidates for unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.76%
Tags
none
Rhea-AI Summary

Clearmind Medicine Inc. (CMND) has completed IND-enabling studies for its lead compound, CMND-100, targeting Alcohol Use Disorder (AUD). The company is preparing to submit an Investigational New Drug application to the FDA and the Israeli Ministry of Health, paving the way for its first human clinical trial. The compound is anticipated to significantly reduce alcohol consumption, addressing a critical global health issue that costs the U.S. $250 billion annually. Clearmind holds patents for CMND-100 in various regions, indicating strong intellectual property backing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.88%
Tags
none

FAQ

What is the current stock price of Clearmind Medicine Common Shares (CMND)?

The current stock price of Clearmind Medicine Common Shares (CMND) is $1.22 as of December 23, 2024.

What is the market cap of Clearmind Medicine Common Shares (CMND)?

The market cap of Clearmind Medicine Common Shares (CMND) is approximately 5.3M.

What is Clearmind Medicine Inc.'s primary area of focus?

Clearmind Medicine Inc. focuses on the discovery and development of novel psychedelic-derived therapeutics to address widespread and under-treated health problems, particularly alcohol use disorder (AUD).

What is CMND-100?

CMND-100 is Clearmind's flagship MEAI-based compound aimed at treating alcohol use disorder. It has shown promising pre-clinical results in reducing binge drinking without causing hallucinations.

What recent clinical developments has Clearmind made?

The Israeli Ministry of Health recently approved a Phase I/IIa clinical trial for CMND-100 to treat alcohol use disorder, marking a significant milestone in its development.

What are the key features of Clearmind's intellectual property portfolio?

Clearmind's intellectual property portfolio includes eighteen patent families and 27 granted patents, with recent additions focusing on treatments for alcohol use disorder, cocaine addiction, and obesity-related disorders.

What strategic collaborations has Clearmind entered into?

Clearmind has entered exclusive licensing agreements with the Hebrew University of Jerusalem and Yissum Research Development Company, enriching its portfolio with psychedelic compounds for treating addiction and mental health disorders.

What is Clearmind's MEAI-based alcohol substitute beverage program?

Clearmind is developing a proprietary, ethanol-free MEAI-based alcohol substitute beverage. This product aligns with the growing trend towards no- and low-alcohol consumption and aims to offer a health-focused alternative.

Where are Clearmind's shares traded?

Clearmind's shares are traded on Nasdaq under the symbol 'CMND' and on the Frankfurt Stock Exchange under the symbol 'CWY0'.

How can I contact Clearmind Medicine Inc. for more information?

For more information, you can visit their official website at www.clearmindmedicine.com or contact Investor Relations at invest@clearmindmedicine.com.

What is Clearmind's approach to intellectual property?

Clearmind is committed to expanding and protecting its intellectual property by filing additional patents and remaining opportunistic regarding the acquisition of new IP assets.

How does Clearmind ensure the safety of its novel compounds?

Clearmind's novel compounds undergo rigorous pre-clinical and clinical trials to ensure safety and efficacy before potential commercialization.

Clearmind Medicine Inc. Common Shares

Nasdaq:CMND

CMND Rankings

CMND Stock Data

5.30M
4.07M
17.32%
4.61%
Biotechnology
Healthcare
Link
United States of America
Vancouver